Shandong Jincheng Pharmaceutical Group Co., Ltd (SHE:300233)
China · Delayed Price · Currency is CNY 11.33
-0.21 (-1.82%)
Nov 13, 2026, 1:55 PM CST
SHE:300233 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 4,298 | 5,307 | 4,552 | 6,336 | 8,741 | 11,167 | |
Market Cap Growth | -34.96% | 16.58% | -28.16% | -27.51% | -21.73% | 51.12% |
Enterprise Value | 3,632 | 5,013 | 4,269 | 5,949 | 8,638 | 10,916 |
Last Close Price | 11.54 | 13.86 | 11.59 | 15.77 | 21.40 | 27.14 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 25.77 | 120.10 | 23.13 | 36.27 | 31.98 | 103.41 |
Forward PE | - | 24.24 | 24.24 | 24.24 | 24.24 | 24.24 |
PS Ratio | 1.54 | 1.94 | 1.35 | 1.79 | 2.49 | 3.56 |
PB Ratio | 1.15 | 1.43 | 1.19 | 1.68 | 2.39 | 3.25 |
P/TBV Ratio | 1.36 | 1.70 | 1.40 | 2.00 | 2.77 | 3.79 |
P/FCF Ratio | 13.89 | 24.26 | 29.56 | 19.73 | - | 182.94 |
P/OCF Ratio | 10.79 | 16.60 | 15.35 | 9.54 | 34.19 | 25.54 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 1.31 | 1.83 | 1.26 | 1.68 | 2.46 | 3.48 |
EV/EBITDA Ratio | 7.30 | 12.37 | 7.33 | 11.32 | 13.83 | 24.63 |
EV/EBIT Ratio | 20.07 | 58.15 | 16.09 | 27.05 | 23.14 | 48.74 |
EV/FCF Ratio | 11.78 | 22.92 | 27.72 | 18.52 | - | 178.82 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.06 | 0.10 | 0.14 | 0.15 | 0.18 | 0.19 |
Debt / EBITDA Ratio | 0.42 | 0.93 | 0.88 | 1.05 | 1.03 | 1.46 |
Debt / FCF Ratio | 0.68 | 1.74 | 3.35 | 1.73 | - | 10.69 |
Net Debt / Equity Ratio | -0.19 | -0.14 | -0.10 | -0.12 | -0.06 | -0.10 |
Net Debt / EBITDA Ratio | -1.44 | -1.27 | -0.69 | -0.90 | -0.33 | -0.74 |
Net Debt / FCF Ratio | -2.31 | -2.36 | -2.61 | -1.46 | 1.76 | -5.38 |
Asset Turnover | 0.56 | 0.51 | 0.59 | 0.60 | 0.63 | 0.61 |
Inventory Turnover | 3.76 | 3.41 | 3.76 | 3.84 | 3.98 | 4.57 |
Quick Ratio | 1.52 | 1.30 | 1.32 | 1.14 | 0.98 | 1.18 |
Current Ratio | 2.04 | 1.71 | 1.84 | 1.48 | 1.36 | 1.51 |
Return on Equity (ROE) | 4.10% | 1.12% | 5.46% | 5.20% | 8.05% | 3.56% |
Return on Assets (ROA) | 2.28% | 1.00% | 2.88% | 2.34% | 4.20% | 2.73% |
Return on Invested Capital (ROIC) | 4.37% | 1.41% | 6.09% | 5.58% | 9.40% | 4.75% |
Return on Capital Employed (ROCE) | 4.70% | 2.20% | 6.10% | 5.10% | 9.10% | 5.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 3.88% | 0.83% | 4.32% | 2.76% | 3.13% | 0.97% |
FCF Yield | 7.20% | 4.12% | 3.38% | 5.07% | -1.35% | 0.55% |
Dividend Yield | 2.21% | 1.79% | 2.08% | 1.21% | 0.66% | 0.68% |
Payout Ratio | 41.19% | 367.78% | 66.91% | 47.80% | 38.33% | 97.41% |
Buyback Yield / Dilution | 8.63% | 2.70% | 2.53% | -0.84% | 0.17% | 0.60% |
Total Shareholder Return | 10.80% | 4.48% | 4.61% | 0.38% | 0.82% | 1.28% |